Biotechnology

Thursday Jun 12, 2025 - 12:54 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. The company recently announced its financial results for the first quarter of 2025 as well as accomplishments representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. “Our strategic focus remains on advancing our clinical programs, and we…

Tuesday Jun 10, 2025 - 12:52 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of…

Friday Jun 06, 2025 - 1:33 pm

InvestorNewsBreaks – Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. INBS was featured in a recent article that reads, “By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings… The company’s vision is to redefine drug screening by…

Wednesday Jun 04, 2025 - 3:34 pm

InvestorNewsBreaks – Adageis Empowers Providers with Actionable Insights for Value-Based Care Success

Adageis, a growing healthcare technology company, offers a unique streamlined and AI-powered software solution designed to make the shift toward value-based care simpler for healthcare practices. “At the core of the company’s offering is the ProActive Care Platform, a patented, AI-centric engine that enables providers, health systems, ACOs, and CINs to identify and act on high-value opportunities within their existing operations,” reads a recent article.…

Friday May 30, 2025 - 3:07 pm

InvestorNewsBreaks – Adageis’ AI-Powered Insights Aim to Improve Outcomes, Revenue Forecasting

Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at providers shifting from fee-for-service to value-based care. “At the core of the company’s offering is its ProActive Care Platform, which combines predictive analytics with real-time data integration to improve both clinical and financial outcomes,” reads a recent article. “The platform’s Patented Risk Engine (‘PRE’) enables users to forecast revenue based…

Thursday May 22, 2025 - 3:31 pm

InvestorNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of…

Thursday May 22, 2025 - 2:50 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy…

Thursday May 15, 2025 - 3:36 pm

InvestorNewsBreaks – Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based…

Thursday May 15, 2025 - 2:32 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch…

Thursday May 15, 2025 - 12:54 pm

InvestorNewsBreaks – Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success. According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with…

Friday May 09, 2025 - 2:51 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a…

Thursday May 08, 2025 - 3:32 pm

InvestorNewsBreaks – Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers…

Tuesday Apr 29, 2025 - 12:20 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With…

Tuesday Apr 29, 2025 - 11:14 am

InvestorNewsBreaks – Adageis Is Reshaping Patient Care Through Smart Tech

Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to eliminate administrative burdens and enable providers to focus on patients. With simplicity core to its design, the platform empowers healthcare organizations by identifying missed revenue opportunities from insurers and guiding providers to secure rightful payments. Using predictive analytics through its Patented Risk Engine (“PRE”), Adageis enhances steady cash flow…

Friday Apr 11, 2025 - 3:37 pm

InvestorNewsBreaks – Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care…

Friday Apr 04, 2025 - 3:35 pm

InvestorNewsBreaks – Adageis Positioned to Scale Impact in Health Technology Landscape

Adageis is a forward-thinking healthcare technology company that is transforming patient care with AI-driven software solutions. The company recently secured $2 million in seed financing and plans to utilize the funding to support upgrades to its backend infrastructure, expand Electronic Health Record (“EHR”) system connectivity, and increase sales efforts to promote rapid growth. Its flagship ProActive Care Platform assists healthcare providers in the transition to…

Tuesday Mar 25, 2025 - 2:00 pm

InvestorNewsBreaks – Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions…

Friday Mar 21, 2025 - 1:48 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The…

Friday Mar 21, 2025 - 12:20 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and…

Wednesday Mar 19, 2025 - 2:01 pm

InvestorNewsBreaks – Adageis Navigates Complexities of Value-Based Care with Tailored Solution

Adageis was featured in a recent article that discussed the company’s positioning as healthcare shifts toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. “While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate,” the article reads. “One of the major challenges in the marketplace is…

Tuesday Mar 18, 2025 - 12:26 pm

InvestorNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a recent article. “With a diversified pipeline, multiple orphan and…

Friday Mar 14, 2025 - 2:26 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body's immune response. Calidi's pipeline includes three key therapies — RTNova, SuperNova…

Friday Mar 07, 2025 - 1:15 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the largest ALS biomarker repositories, which includes data from over 4,300 ALS patients. This collaboration will enable Clene to compare NfL levels in patients treated…

Wednesday Mar 05, 2025 - 3:22 pm

InvestorNewsBreaks – Adageis: Shaping the Future of Healthcare with AI-Powered Solutions

Adageis offers AI-driven solutions that help providers transition to and optimize value-based care models. “Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services rendered. This approach incentivizes proactive care, chronic disease management and overall cost efficiency,” a recent article explains. “Adageis, a…

Wednesday Mar 05, 2025 - 2:33 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent…

Thursday Feb 27, 2025 - 3:15 pm

InvestorNewsBreaks – Adageis Tackling Healthcare’s Value-Based Shift with AI-Driven Insights, Seamless Integration

Adageis, a forward-thinking healthcare technology company, is bringing AI-driven solutions that help providers harness data to improve care efficiency and financial performance amid an industry shift from fee-for-service models to value-based care. “A major hurdle in value-based care is identifying high-risk patients before they require costly interventions. Adageis addresses this with its Patented Risk Engine (‘PRE’), which analyzes clinical and demographic data to flag individuals…

Thursday Feb 20, 2025 - 1:05 pm

InvestorNewsBreaks – Adageis: Championing the Future of Healthcare with Powerful AI Tools

Adageis is positioned for opportunity as artificial intelligence reshapes healthcare. The technology company offers “flexible AI-centric software solutions for healthcare systems and providers in an easy-to-use application driving higher revenue… Its powerful and patented AI-centric ProActive Care Platform integrates seamlessly into existing workflows, making it an ideal partner for organizations navigating the shift toward value-based care,” reads a recent article. “Adageis’ proactive efficiency tools enable…

Friday Feb 14, 2025 - 3:41 pm

InvestorNewsBreaks – Adageis Bringing AI Solutions to Identify High-Risk Patients, Address Care Gaps

Adageis is reshaping the healthcare landscape, offering solutions designed to streamline workflows and align incentives with quality care outcomes. “Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (‘ACOs’), Clinically Integrated Networks (‘CINs’), and Independent Physician Associations (‘IPAs’) with the tools to deliver high-quality care while meeting…

Tuesday Feb 11, 2025 - 1:19 pm

InvestorNewsBreaks – Adageis Seizing Opportunity in AI-Driven Healthcare Innovation

Adageis is positioned to capitalize as artificial intelligence (“AI”) plays a crucial role in meeting quality metrics, reducing costs and improving patient outcomes in the transition toward value-based healthcare. While the sector faces challenges — such as integrating AI tools into existing systems, ensuring data security and navigating regulatory frameworks — innovators like Adageis, a forward-thinking healthcare technology company, are stepping in to bridge the…

Wednesday Feb 05, 2025 - 3:00 pm

InvestorNewsBreaks – Astiva Health’s Focus on Multilingual Support, Tailored Solutions Driving Its Success

Astiva Health, now serves more than 30,000 members, an increase that reflects the growing demand for the company’s unique, culturally aligned health care model. “The increase in membership comes as Astiva earned a prestigious 4-star CMS rating for 2025, placing it among the top-rated Medicare Advantage providers in California,” reads a recent article. “This membership surge reflects the growing demand for Astiva’s culturally aligned health…

Wednesday Jan 22, 2025 - 2:58 pm

InvestorNewsBreaks – Adageis at Forefront of Shift to Value-Based Care

Adageis is structured to support providers during a transformation of the U.S. healthcare system, shifting from fee-for-service models to value-based care. The company’s unique offering of tools and solutions simplify the necessary moves, including AI-driven analytics and patient-focused care solutions. “This transition prioritizes quality outcomes over service volume but requires a dramatic overhaul of infrastructure, culture and operations. Adageis, a forward-thinking healthcare technology company, is…

Monday Jan 13, 2025 - 2:46 pm

InvestorNewsBreaks – Adageis’s Platform Empowering Organizations to Adjust to New Risk-Scoring Dynamics

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model. “The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage… The more precise structure…

Monday Jan 13, 2025 - 10:32 am

InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) to Present at Sequire Investor Summit 2025

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, announced that CEO Bryan Kobel will present a corporate overview at the Sequire Investor Summit 2025. The conference will take place Jan. 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. To view the full press release, visit: https://ibn.fm/iz2M1 About TC BioPharm Holdings…

Wednesday Jan 08, 2025 - 2:16 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to…

Friday Jan 03, 2025 - 2:32 pm

InvestorNewsBreaks – Adageis Is Reshaping Patient Care Through AI-Centric Approach

Adageis, a forward-thinking healthcare technology company, is ramping up patient care through flexible AI-centric software solutions for systems and providers, including accountable care organizations (“ACOs”), clinically integrated networks (“CINs”) and independent physician associations (“IPAs”). With a unique proposition in the space, the company is actively improving healthcare delivery and increasing value-based care revenue by streamlining operations via its ProActive Care Platform. “Integrating AI and machine…

Friday Dec 27, 2024 - 1:35 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to…

Thursday Dec 26, 2024 - 3:40 pm

InvestorNewsBreaks – Why Adageis Is ‘One to Watch’

Adageis focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector. “With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training,” reads a recent article. “This approach reduces barriers to adoption and…

Thursday Dec 26, 2024 - 2:37 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently received additional written guidance and a roadmap from the U.S. Food and Drug Administration’s (“FDA”) Division of Neurology 1 regarding a potential accelerated approval pathway for…

Friday Dec 20, 2024 - 2:57 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials

Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt…

Wednesday Dec 11, 2024 - 1:50 pm

InvestorNewsBreaks – Astiva Health Eyes Continued Momentum on Heels of Remarkable Growth

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025. The momentum is expected to build upon the record-setting performance already achieved this year in terms of network and membership expansion. “According to a company news release, membership is expected to grow by 70% or 7,000 members, a major increase…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions